Company Overview and News

3
6 Reasons to Invest in WellCare Health for Portfolio Boost

54m zacks
Estimates for WellCare Health Plans, Inc. (WCG - Free Report) have been revised upward over the past 30 days, reflecting analysts' optimism on the stock. The stock has seen the Zacks Consensus Estimate for 2019 earnings move 1.6% north over the same time frame. The company is poised to gain from an expanding Medicaid business as government is increasingly turning to private players in order to manage costs of this program.
UAM MOH WCG ANTM UNH UAMCP

3
Has UnitedHealth Group (UNH) Outpaced Other Medical Stocks This Year?

2h zacks
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has UnitedHealth Group (UNH - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
UNH

3
UnitedHealth warns hospitals about Envision ER contracts

17h channelnewsasia
UnitedHealth Group Inc will treat emergency room and other hospital services performed by Envision Healthcare as out-of-network claims beginning next year after failing to reach a new contract agreement with the staffing company, UnitedHealth said on Monday.
UNH

3
UnitedHealth warns hospitals about Envision ER contracts

18h reuters
NEW YORK (Reuters) - UnitedHealth Group Inc will treat emergency room and other hospital services performed by Envision Healthcare as out-of-network claims beginning next year after failing to reach a new contract agreement with the staffing company, UnitedHealth said on Monday.
UNH

3
3 Strategies DaVita Is Using To Beat The 'Retail Apocalypse'

2018-09-24 seekingalpha
Editor's note: Seeking Alpha is proud to welcome Eli Schultz as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more »
UNH

68
Top Analyst Upgrades and Downgrades: Abbott Labs, Avon, Caesars, Comcast, Rowan, UnitedHealth, Vonage and More

2018-09-24 247wallst - 2
Stocks have hit all-time highs, but they were indicated marginally lower on Monday after trade tariffs are set to kick in against China. Many investors have seen lower upside from buying on market pullbacks than in prior years, and now they have to consider how they want to have their investments positioned for the rest of 2018 and as 2019 approaches.
WFCNP TXRH EAT APD CCV UAA KRYS AVP DRI CCZ AMD ABT CMCSK ABT WFC AGTC RDC CMCSA NBEV UNFI UA ABRW CZR CCV.CL MU TRI COHU UNH

8
UnitedHealth Group (UNH) Gains As Market Dips: What You Should Know

2018-09-21 zacks
In the latest trading session, UnitedHealth Group (UNH - Free Report) closed at $266.70, marking a +0.11% move from the previous day. The stock outpaced the S&P 500's daily loss of 0.04%. Meanwhile, the Dow gained 0.33%, and the Nasdaq, a tech-heavy index, lost 0.51%.
AOBC SPG CLBS UNH EOG

47
The Essence Of The 'New' Modern Corporation: Free Cash Flow

2018-09-20 seekingalpha
The source of the "new" Modern Corporation has been the big "High Tech" firms, the major ones being labeled the FAANGs, made up of Facebook, Apple, Amazon, Netflix and Alphabet(Google).
BRK.A FB AMZN GOOGL AAPL NFLX GOOG UNH

19
Market Extra: Dow’s first record since January powered by surge in Apple’s stock

2018-09-20 marketwatch
The Dow Jones Industrial Average just marked its first intraday all-time high since January, the resumption of a record run for the blue-chip index that had taken a nearly eight-month pause.
GEC GE BOE AAPL GNE BA UNH

13
Health care ETF surges toward record in a broad sector rally

2018-09-18 marketwatch
The SPDR Health Care Select Sector ETF XLV, +0.68% rose 0.7% toward a record high in afternoon trade Tuesday, with 55 of its 63 equity components gaining ground. Among the ETF's (XLV) members which are also Dow Jones Industrial Average DJIA, +0.86% components, Pfizer Inc.'s stock PFE, +1.22% shot up 1.5%, putting it on track to close at the highest level since December 2001. Also, shares of Johnson & Johnson JNJ, +0.
PFZ ABBV ABMD 500680 UNH PFE PFIZER ABBV

16
3 Cheap Stocks to Buy Before They Skyrocket

2018-09-17 investorplace
The S&P 500 has risen nearly 10% this year, but its increase over the past few years has had a substantial impact on valuations. Notably, ever since the S&P’s upward rise in 2009, the average price-earnings ratio has increased significantly, from just under 15.5 in 2010 to a high of over 25 today.
SNI DISCB DISCA NFLX DISCK CVS MU MS UNH ESRX DISC

3
Can UnitedHealth (UNH) Keep the Earnings Surprise Streak Alive?

2018-09-17 zacks
Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering UnitedHealth Group (UNH - Free Report) , which belongs to the Zacks Medical - HMOs industry.
UNH

3
Insperity's Acceleration With Workforce Acceleration

2018-09-17 seekingalpha
Insperity snapped the last piece of its Workforce Acceleration puzzle into place on August 22nd when it announced an agreement with Mylo.
NSP UNH

9
Dow Within Striking Distance of Record High Level: 4 Picks

2018-09-12 zacks
The Dow 30 — one of the equity markets’ most closely watched indexes — commenced September trading on a negative note after two successful months. After ending in negative territory in the first week of this month, the blue-chip index closed in the green on Sep 11. At present, the index is within striking distance of achieving an all-time high. Despite trade war concerns, a robust U.S. economy and strong earnings results bolstered investors’ confidence in the stock markets enabling the Dow to climb out of the rut.
CATR CAT AAPL MSFT UNH

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to UNH / UnitedHealth Group Inc. on message board site Silicon Investor.

Sierra Health Services Sierra Health Services Sierra Health Services Short Stories Short Stories Short Stories
United Health Group United Health Group United Health Group UNH: UnitedHealth Group Inc. UNH: UnitedHealth Group Inc. UNH: UnitedHealth Group Inc.
Gold Stocks that are Unhedged Gold Stocks that are Unhedged Gold Stocks that are Unhedged sunhawk (SNHK) sunhawk (SNHK) sunhawk (SNHK)
AAPL X CMB UNH PEP KO ZBRA Tim Lukeu0027s Position Tradig AAPL X CMB UNH PEP KO ZBRA Tim Lukeu0027s Position Tradig AAPL X CMB UNH PEP KO ZBRA Tim Lukeu0027s Position Tradig P/E of under 6, and only $3.50 -- Unheard of Company P/E of under 6, and only $3.50 -- Unheard of Company P/E of under 6, and only $3.50 -- Unheard of Company
CUSIP: 91324P102